SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending as the FDA issued a Complete Response Letter for its RGX-121 gene therapy for Hunter syndrome, citing trial design concerns and an ongoing clinical hold extended due to a potential adverse event in a related gene therapy utilizing the same AAV vector platform. The community is expressing significant disappointment over the rejection and its impact on RGNX's valuation, while also questioning the FDA's scrutiny of gene therapies and celebrating gains from short positions.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group (CRDO) is experiencing a significant surge following its pre-announcement of substantially increased revenue guidance for the current quarter and strong fiscal year growth projections. This positive outlook is fueling investor excitement, with many anticipating further upside as the company, a key player in AI data center connectivity, continues to benefit from accelerating hyperscaler capital expenditures amidst ongoing discussions about its technological positioning.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending due to its latest earnings, where a revenue miss and softer forward guidance, particularly against a backdrop of ongoing automotive market softness, have disappointed investors. Community discussion centers on the company's valuation, perceived lack of growth beyond pure AI chip plays, and the broader impact of the EV sector slowdown.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is actively discussed after its latest earnings surpassed expectations with record revenue and profitability, propelled by its AI initiatives including Uma. While many anticipate a short squeeze and highlight undervaluation in the evolving gig economy, others voice frustration over the stock's muted response and concerns about client growth in an AI-driven landscape.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is trending after recent earnings revealed strong EPS growth despite a revenue decline, driven by an expanding backlog and numerous new contracts in critical nuclear, defense, and space sectors. While some in the community express frustration over the stock's price action, many view these long-term contract wins and the company's perceived undervaluation as catalysts for substantial future growth.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

AgomAb Therapeutics NV - ADR

AGMB is experiencing heightened attention as a new IPO amid extreme volatility, with community discussions largely focused on its low float potentially fueling a short squeeze.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending after its stock plunged following the abrupt exits of its CFO and general counsel amidst an accounting review and delayed SEC filings, leading to a split in the community between those fearing significant financial issues and others who believe the drastic sell-off presents an overdone buying opportunity.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is seeing significant bullish momentum after a short-seller retracted serious allegations against a major shareholder, driving a rebound and sparking community discussion around an imminent short squeeze and anticipated strong earnings.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

With its upcoming earnings report sparking significant options activity, Fiserv (FISV) is trending amidst a polarized community debate: optimists highlight recent insider and institutional buying alongside deep undervaluation, while skeptics worry about the stock's persistent weakness and broader fintech sector headwinds exacerbated by AI disruption concerns.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is experiencing a significant sell-off after providing weaker-than-expected revenue guidance for the upcoming quarter and fiscal year, despite reporting stronger-than-anticipated earnings and revenue growth. The community is actively debating whether this dip is an overreaction, weighing the company's strong customer retention and large cash reserves against intensifying market fears that AI tools could disrupt the traditional software business model.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Revance Therapeutics surged more than 16% on Monday morning, reaching over a month’s high, leading to a jump in retail chatter on Stocktwits.The surge followed a proposal from privately held Swiss medical aesthetics company Teoxane to acquire the anti-wrinkle injection maker for $3.60 per share in cash.&nbsp;The offer represents a 16% premium over the $3.10-per-share agreement with Crown Laboratories&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rvnc-stock-tanks-after-crown-labs-halves-takeover-price/cJabclHRig">announced</a> last month.Revance has yet to comment publicly on the proposal, but the news triggered a spike in message volume on Stocktwits, where retail sentiment remained cautious with a ‘neutral’ score.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/RVNC_sentiment_and_message_volume_Jan_6_1855360b7a.png" alt="RVNC sentiment and message volume Jan 6.png" width="1318" height="324"><figcaption>RVNC sentiment and message volume Jan 6 as of 10:45 am ET | source: Stocktwits</figcaption></figure>Last year, Crown agreed to purchase Revance for $6.66 per share, but the deal faced delays due to a dispute with Teoxane over Revance’s breach of a 2020 distribution agreement.&nbsp;The agreement had made Revance the exclusive commercialization partner for Teoxane’s dermal fillers. After resolving the dispute, Revance and Crown amended their deal, slashing the takeover price by more than half, reducing it to approximately $323 million.Teoxane currently holds 6.2% of Revance’s outstanding shares.&nbsp;Despite the uptick in shares following the Teoxane proposal, Revance's stock has struggled recently, plunging around 65% last year.Last year, Revance Therapeutics announced the commercial launch of DAXXIFY for injection for the treatment of cervical dystonia, marking its entry into the expanding U.S. therapeutics neurotoxin market, which could play a role in reshaping its future prospects.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Revance Therapeutics Stock’s Retail Sentiment Muted Even As Teoxane Makes Better Offer Than Crown Labs

The offer represents a 16% premium over the $3.10-per-share agreement with Crown Laboratories announced last month.

Equity

Shares of Revance Therapeutics Inc. plummeted over 20% to a four-month low Monday after private skincare firm Crown Laboratories drastically reduced its takeover offer.Crown will now acquire Revance in an all-cash deal valued at $3.10 per share, down from the initial August agreement of $6.66 per share.&nbsp;The revised deal, worth about $325 million in total equity, marks an 18.9% discount to Revance’s Dec. 6 closing price.&nbsp;The acquisition will make Revance a private company, with the deal expected to close in the first quarter of 2025.The price cut follows a notice received by Revance in September alleging violations of an exclusive distribution agreement with Teoxane.&nbsp;Both companies acknowledged that these violations could significantly impact Revance’s profitability and cash flows, prompting the adjustment.<figure class="image"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_09_at_11_31_10_AM_0b2b5cca48.png" alt="Screenshot 2024-12-09 at 11.31.10 AM.png" width="1314" height="320"><figcaption>RVNC sentiment and message volume on Dec. 9 as of 11:30 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned sharply bearish, accompanied by ‘extremely high’ message volume as investors expressed frustration.&nbsp;Posts highlighted disappointment with the slashed valuation and uncertainty about Revance’s future.<stembedurl>https://stocktwits.com/Hedgieguy75/message/595701639</stembedurl><stembedurl>https://stocktwits.com/jamstah/message/595671321</stembedurl>Revance, known for its anti-wrinkle injections, has faced a challenging year, with shares down 56.5% so far this year.For updates and corrections email newsroom[at]stocktwits[dot]com.

Revance Therapeutics Stock Plummets To 4-Month Low As Crown Labs Halves Takeover Offer: Retail Fumes

The price cut follows a notice received by Revance in September alleging violations of an exclusive distribution agreement with Teoxane.

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Revance Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

RVNC
Revance Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RVNC News

RVNCRevance Therapeutics Inc